{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:09:05Z","timestamp":1788865745560,"version":"build-2803163510"},"posted":{"date-parts":[[2026,9,8]]},"group-title":"In Review","reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,23]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Rationale:\n Fibroblast activation protein (FAP) is a prominent transmembrane protein in the tumor microenvironment (TME) that promotes tumorigenesis. FAP has been a recent target for radionuclide-conjugated peptides for PET imaging and targeted radionuclide therapy (TRT). The objective of this study is to develop a theranostic approach using [\n                  <sup>64\/67<\/sup>\n                  Cu]-FAP2287 in combination with immunotherapy (IMT) to treat triple-negative breast cancer (TNBC).\nMethods\n 4T1 tumor-bearing BALB\/c mice (N\u2009=\u200920) were injected and imaged with 100\u00b5Ci [\n                  <sup>64<\/sup>\n                  Cu]-FAP2287 PET at 1, 4, and 24h to quantify baseline FAP expression followed by autoradiography. 4T1-tumor bearing BALB\/c mice (N\u2009=\u200942) were divided into Control, IMT, 800\u00b5Ci [\n                  <sup>67<\/sup>\n                  Cu]-FAP2287 or 4)[\n                  <sup>67<\/sup>\n                  Cu]-FAP2287\u2009+\u2009IMT and 1600\u00b5Ci [\n                  <sup>67<\/sup>\n                  Cu]-FAP2287, or [\n                  <sup>67<\/sup>\n                  Cu]-FAP2287\u2009+\u2009IMT (N\u2009=\u20095\u201310\/group) and imaged with [\n                  <sup>64<\/sup>\n                  Cu]-FAP2287 PET followed by treatment. All [\n                  <sup>67<\/sup>\n                  Cu]-FAP2287 groups were imaged with SPECT at 4, 24, and 48h. Tumor growth and survival rates were monitored. Standard uptake values (SUV) quantified, statistical analysis and probability of survival were done with significance at p\u2009&lt;\u20090.05.\nResults\n At baseline, there was a strong positive correlation between [\n                  <sup>64<\/sup>\n                  Cu]-FAP2287 PET SUV\n                  <sub>Mean<\/sub>\n                  and autoradiography (R\n                  <sup>2<\/sup>\n                  \u2009=\u20090.7806,p\u2009&lt;\u20090.001). No changes in [\n                  <sup>67<\/sup>\n                  Cu]-FAP2287 retention over time was observed following the IMT. [\n                  <sup>64<\/sup>\n                  Cu]-FAP2287 SUV\n                  <sub>Mean<\/sub>\n                  proved to be a reliable predictor of survival with 800\u00b5Ci (R\n                  <sup>2<\/sup>\n                  \u2009=\u20090.84,p\u2009=\u20090.03) and 1600\u00b5Ci (R\n                  <sup>2<\/sup>\n                  \u2009=\u20090.62,p\u2009=\u20090.01). FAP-TRT increased survival compared to controls and IMT. 1600\u00b5Ci [\n                  <sup>67<\/sup>\n                  Cu]-FAP2287\u2009+\u2009IMT significantly decreased tumor volume (p\u2009=\u20090.0003) and increased survival (p\u2009=\u20090.0005) compared to [\n                  <sup>67<\/sup>\n                  Cu]-FAP2287.\nConclusion\n We can noninvasively target and predict response to FAP radiolabeled with elementally paired theranostic probe, [\n                  <sup>64\/67<\/sup>\n                  Cu]-FAP2287 in TNBC. IMT synergistically increased response to FAP-TRT and can guide personalized approaches to improve treatment efficacy.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10790344\/v1","type":"posted-content","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:29:19Z","timestamp":1788863359000},"source":"Crossref","is-referenced-by-count":0,"title":["[64\/67Cu]-FAP theranostics in combination with immunotherapy in a preclinical model of TNBC"],"prefix":"10.21203","author":[{"given":"Sharmila","family":"Sridhar","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Tekin","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison","family":"Hunt","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E.","family":"Lynch","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Gallegos","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julienne L.","family":"Carstens","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Lapi","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-3966","authenticated-orcid":false,"given":"Anna","family":"Sorace","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer","volume":"8","author":"Sia J","year":"2020","unstructured":"Sia J, Szmyd R, Hau E, Gee HE (2020) Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer. Front Cell Dev Biol. ;8","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook","volume":"15","author":"Obidiro O","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO (2023) Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. ;15(7)","journal-title":"Pharmaceutics"},{"issue":"1","key":"ref3","article-title":"Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities","volume":"57","author":"Dass SA","year":"2021","unstructured":"Dass SA, Tan KL, Rajan RS, Mokhtar NF, Adzmi ERM, Rahman WFWA et al (2021) Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities. Medicina-Lithuania. ;57(1)","journal-title":"Medicina-Lithuania"},{"key":"ref4","article-title":"Triple Negative Breast Cancer - An Overview","author":"Aysola K","year":"2013","unstructured":"Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V et al (2013) Triple Negative Breast Cancer - An Overview. Hereditary Genet. ;2013(Suppl 2).","journal-title":"Hereditary Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"681476","DOI":"10.3389\/fonc.2021.681476","article-title":"Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer","volume":"11","author":"Ensenyat-Mendez M","year":"2021","unstructured":"Ensenyat-Mendez M, Llin\u00e0s-Arias P, Orozco JIJ, \u00cd\u00f1iguez-Mu\u00f1oz S, Salomon MP, Ses\u00e9 B et al (2021) Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. Front Oncol 11:681476","journal-title":"Front Oncol"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami P","year":"2022","unstructured":"Zagami P, Carey LA (2022) Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer 8(1):95","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","article-title":"Triple-negative breast cancer: therapeutic options","volume":"8","author":"Cleator S","year":"2007","unstructured":"Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8(3):235\u2013244","journal-title":"Lancet Oncol"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807\u2013821","journal-title":"Cell Mol Immunol"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163972","article-title":"Recent Advances and Challenges in Cancer Immunotherapy","volume":"14","author":"Peterson C","year":"2022","unstructured":"Peterson C, Denlinger N, Yang Y (2022) Recent Advances and Challenges in Cancer Immunotherapy. Cancers (Basel). ;14(16)","journal-title":"Cancers (Basel)"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00262-019-02310-2","article-title":"Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors","volume":"68","author":"Nadal E","year":"2019","unstructured":"Nadal E, Massuti B, D\u00f3mine M, Garc\u00eda-Campelo R, Cobo M, Felip E (2019) Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 68(3):341\u2013352","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"17","key":"ref12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf D","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al (2015) Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 33(17):1889\u20131894","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte A","year":"2019","unstructured":"Rotte A (2019) Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 38(1):255","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar P","year":"2016","unstructured":"Kumar P, Aggarwal R (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293(2):247\u2013269","journal-title":"Arch Gynecol Obstet"},{"issue":"15 Pt 1","key":"ref15","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent R","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"216894","DOI":"10.1016\/j.canlet.2024.216894","article-title":"Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies","volume":"591","author":"El-Tanani M","year":"2024","unstructured":"El-Tanani M, Rabbani SA, Babiker R, Rangraze I, Kapre S, Palakurthi SS et al (2024) Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Lett 591:216894","journal-title":"Cancer Lett"},{"issue":"Pt 23","key":"ref17","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill FR","year":"2012","unstructured":"Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(Pt 23):5591\u20135596","journal-title":"J Cell Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"111436","DOI":"10.1016\/j.biopha.2021.111436","article-title":"PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines","volume":"138","author":"Lotfinejad P","year":"2021","unstructured":"Lotfinejad P, Kazemi T, Safaei S, Amini M, Roshani Asl E, Baghbani E et al (2021) PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomed Pharmacother 138:111436","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41417-021-00318-4","article-title":"Cancer-associated fibroblasts: overview, progress, challenges, and directions","volume":"28","author":"Ping Q","year":"2021","unstructured":"Ping Q, Yan R, Cheng X, Wang W, Zhong Y, Hou Z et al (2021) Cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther 28(9):984\u2013999","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3390\/cancers7040902","article-title":"Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth","volume":"7","author":"Shiga K","year":"2015","unstructured":"Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H (2015) Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. Cancers (Basel) 7(4):2443\u20132458","journal-title":"Cancers (Basel)"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald AA","year":"2020","unstructured":"Fitzgerald AA, Weiner LM (2020) The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev 39(3):783\u2013803","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/mc.23205","article-title":"The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy","volume":"59","author":"Piper M","year":"2020","unstructured":"Piper M, Mueller AC, Karam SD (2020) The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy. Mol Carcinog 59(7):754\u2013765","journal-title":"Mol Carcinog"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9 BM","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW et al (2023) Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging 50(7):1906\u20131918","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers13133357","article-title":"Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation","volume":"13","author":"Zheng H","year":"2021","unstructured":"Zheng H, Siddharth S, Parida S, Wu X, Sharma D (2021) Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. Cancers (Basel) 13:13","journal-title":"Cancers (Basel)"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"e0169105","DOI":"10.1371\/journal.pone.0169105","article-title":"The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases","volume":"11","author":"Errarte P","year":"2016","unstructured":"Errarte P, Guarch R, Pulido R, Blanco L, Nunes-Xavier CE, Beitia M et al (2016) The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases. PLoS ONE 11(12):e0169105","journal-title":"PLoS ONE"},{"issue":"17","key":"ref26","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment","volume":"28","author":"Kleinendorst SC","year":"2022","unstructured":"Kleinendorst SC, Oosterwijk E, Bussink J, Westdorp H, Konijnenberg MW, Heskamp S (2022) Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment. Clin Cancer Res 28(17):3652\u20133657","journal-title":"Clin Cancer Res"},{"issue":"45","key":"ref27","doi-asserted-by":"crossref","first-page":"28316","DOI":"10.1073\/pnas.2009960117","article-title":"Harnessing (64)Cu\/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy","volume":"117","author":"Kein\u00e4nen O","year":"2020","unstructured":"Kein\u00e4nen O, Fung K, Brennan JM, Zia N, Harris M, van Dam E et al (2020) Harnessing (64)Cu\/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy. Proc Natl Acad Sci U S A 117(45):28316\u201328327","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3892\/mmr.2015.3197","article-title":"Fibroblast activation protein \u03b1 in tumor microenvironment: recent progression and implications (review)","volume":"11","author":"Zi F","year":"2015","unstructured":"Zi F, He J, He D, Li Y, Yang L, Cai Z (2015) Fibroblast activation protein \u03b1 in tumor microenvironment: recent progression and implications (review). Mol Med Rep 11(5):3203\u20133211","journal-title":"Mol Med Rep"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1039\/D4MD00591K","article-title":"Enhancing the radionuclide theranostic concept through the radiohybrid approach","volume":"16","author":"Kr\u00f6nke T","year":"2025","unstructured":"Kr\u00f6nke T, Kopka K, Mamat C (2025) Enhancing the radionuclide theranostic concept through the radiohybrid approach. RSC Med Chem 16(5):1856\u20131864","journal-title":"RSC Med Chem"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12020205","article-title":"Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects","volume":"12","author":"Danieli R","year":"2022","unstructured":"Danieli R, Milano A, Gallo S, Veronese I, Lascialfari A, Indovina L et al (2022) Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects. J Pers Med. ;12(2)","journal-title":"J Pers Med"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7150\/thno.62851","article-title":"Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs","volume":"12","author":"Miller C","year":"2022","unstructured":"Miller C, Rousseau J, Ramogida CF, Celler A, Rahmim A, Uribe CF (2022) Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics 12(1):232\u2013259","journal-title":"Theranostics"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold","volume":"4","author":"Jansen K","year":"2013","unstructured":"Jansen K, Heirbaut L, Cheng JD, Joossens J, Ryabtsova O, Cos P et al (2013) Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Med Chem Lett 4(5):491\u2013496","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: combining imaging and therapy","volume":"22","author":"Kelkar SS","year":"2011","unstructured":"Kelkar SS, Reineke TM (2011) Theranostics: combining imaging and therapy. Bioconjug Chem 22(10):1879\u20131903","journal-title":"Bioconjug Chem"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski D","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E et al (2022) Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging 49(11):3651\u20133667","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski D","year":"2023","unstructured":"Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A et al (2023) Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. Eur J Nucl Med Mol Imaging 50(9):2621\u20132635","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0969-8051(96)00157-6","article-title":"Efficient production of high specific activity 64Cu using a biomedical cyclotron","volume":"24","author":"McCarthy DW","year":"1997","unstructured":"McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS et al (1997) Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 24(1):35\u201343","journal-title":"Nucl Med Biol"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12935-020-01625-w","article-title":"CD4 T-cell immune stimulation of HER2\u2009+\u2009breast cancer cells alters response to trastuzumab in vitro","volume":"20","author":"Song PN","year":"2020","unstructured":"Song PN, Mansur A, Dugger KJ, Davis TR, Howard G, Yankeelov TE et al (2020) CD4 T-cell immune stimulation of HER2\u2009+\u2009breast cancer cells alters response to trastuzumab in vitro. Cancer Cell Int 20(1):544","journal-title":"Cancer Cell Int"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7150\/thno.89206","article-title":"[(89)Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models","volume":"14","author":"Gallegos CA","year":"2024","unstructured":"Gallegos CA, Lu Y, Clements JC, Song PN, Lynch SE, Mascioni A et al (2024) [(89)Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models. Theranostics 14(3):911\u2013923","journal-title":"Theranostics"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1038\/s41598-024-52897-5","article-title":"Dual anti-HER2\/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC","volume":"14","author":"Song PN","year":"2024","unstructured":"Song PN, Lynch SE, DeMellier CT, Mansur A, Gallegos CA, Wright BD et al (2024) Dual anti-HER2\/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC. Sci Rep 14(1):3771","journal-title":"Sci Rep"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"e0224137","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko E","year":"2019","unstructured":"Demidenko E, Miller TW (2019) Statistical determination of synergy based on Bliss definition of drugs independence. PLoS ONE 14(11):e0224137","journal-title":"PLoS ONE"},{"issue":"6","key":"ref41","article-title":"iRECIST and atypical patterns of response to immuno-oncology drugs","volume":"10","author":"Ramon-Patino JL","year":"2022","unstructured":"Ramon-Patino JL, Schmid S, Lau S, Seymour L, Gaudreau PO, Li JJN et al (2022) iRECIST and atypical patterns of response to immuno-oncology drugs. J Immunother Cancer. ;10(6)","journal-title":"J Immunother Cancer"},{"key":"ref42","author":"Yang1 L","year":"2020","unstructured":"Yang1 L, Zhou1 T-y, Yong1 L, Zhu X 2 et al (2020) Feng1 Y, Fu1 Y,. Disease progression model of 4T1 metastatic breast cancer. Journal of Pharmacokinetics and Pharmacodynamics. ;47"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00259-023-06338-6","article-title":"Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?","volume":"50","author":"Chakravarty R","year":"2023","unstructured":"Chakravarty R, Song W, Chakraborty S, Cai W (2023) Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best? Eur J Nucl Med Mol Imaging 50(10):2935\u20132939","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"ref44","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers","volume":"25","author":"Hagemann UB","year":"2019","unstructured":"Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V et al (2019) Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res 25(15):4723\u20134734","journal-title":"Clin Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"110043","DOI":"10.1016\/j.msec.2019.110043","article-title":"(177)Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer","volume":"105","author":"Gibbens-Bandala B","year":"2019","unstructured":"Gibbens-Bandala B, Morales-Avila E, Ferro-Flores G, Santos-Cuevas C, Mel\u00e9ndez-Alafort L, Trujillo-Nolasco M et al (2019) (177)Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer. Mater Sci Eng C Mater Biol Appl 105:110043","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"4","key":"ref46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19040925","article-title":"(212)Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models","volume":"19","author":"Kasten BB","year":"2018","unstructured":"Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR et al (2018) (212)Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci. ;19(4)","journal-title":"Int J Mol Sci"},{"issue":"1","key":"ref47","article-title":"Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment","volume":"15","author":"Kerr CP","year":"2022","unstructured":"Kerr CP, Grudzinski JJ, Nguyen TP, Hernandez R, Weichert JP, Morris ZS (2022) Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment. Pharmaceutics. ;15(1)","journal-title":"Pharmaceutics"},{"issue":"9","key":"ref48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094843","article-title":"Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer","volume":"22","author":"Vito A","year":"2021","unstructured":"Vito A, Rathmann S, Mercanti N, El-Sayes N, Mossman K, Valliant J (2021) Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. Int J Mol Sci. ;22(9)","journal-title":"Int J Mol Sci"},{"issue":"2","key":"ref49","first-page":"10","article-title":"Mohsen Beheshti. Pre-treatment 68 Ga-PSMA-11 PET\/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival","volume":"26","author":"Roya Eisazadeh SAM","year":"2024","unstructured":"Roya Eisazadeh SAM, Gregor Schwieghofer-Zwink L, Hehenwarter G, Rendl S, Gampenrieder R, Greil C, Pirich (2024) Mohsen Beheshti. Pre-treatment 68 Ga-PSMA-11 PET\/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival. Mol Imaging Biology 26(2):10","journal-title":"Mol Imaging Biology"},{"key":"ref50","article-title":"la supervivencia global con el PSA s\u00e9rico y los criterios de respuesta basados en PSMA PET","author":"Ozkan a BDb E","year":"2025","unstructured":"Ozkan a BDb E, Soydal a C, Araz a M, Dursun a E, Kucuk a NO (2025) Y. Urun c. Prediction of [177Lu]Lu-PSMA-617 treatment response with [68Ga]Ga-PSMA-11 PET-derived variables and correlation of the overall survival with serum PSA and PSMA PET-based response criteriaPredicci\u00f3n de la respuesta al tratamiento con [177Lu]Lu-PSMA-617 mediante variables derivadas de [68Ga]Ga-PSMA-11 PET y correlaci\u00f3n de la supervivencia global con el PSA s\u00e9rico y los criterios de respuesta basados en PSMA PET. Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"ref51","first-page":"8","article-title":"Aboagyea \u2219 Tara D. Barwicka,b RSrsiauWMWSYJERRFWAFFMA. 68Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours","volume":"141","author":"Al-Nahhasb \u2219 Eric O","year":"2019","unstructured":"Al-Nahhasb \u2219 Eric O (2019) Aboagyea \u2219 Tara D. Barwicka,b RSrsiauWMWSYJERRFWAFFMA. 68Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 141:8","journal-title":"Radiother Oncol"},{"issue":"1","key":"ref52","article-title":"Katona, and Daniel A. Pryma. Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET\/CT","volume":"16","author":"Remy Niman, Sophia R","year":"2023","unstructured":"Hwan Lee1 STK, Remy Niman, Sophia R, O\u2019Brien JR, Eads BW (2023) Katona, and Daniel A. Pryma. Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET\/CT. Cancers (Basel). ;16(1)","journal-title":"Cancers (Basel)"},{"issue":"3","key":"ref53","article-title":"Investigating the Theranostic Potential of Elementally Matched [43Sc]Sc-PSMA-617 and [47Sc]Sc-PSMA-617","volume":"23","author":"Lapi SJCPAHRGSTE","year":"2026","unstructured":"Lapi SJCPAHRGSTE (2026) Investigating the Theranostic Potential of Elementally Matched [43Sc]Sc-PSMA-617 and [47Sc]Sc-PSMA-617. Mol pharmaceuticals. ;23(3)","journal-title":"Mol pharmaceuticals"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10790344\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10790344\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:30:09Z","timestamp":1788863409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10790344\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":53,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10790344\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,9,8]]},"subtype":"preprint"}}